Elan Corp. Summary
Elan Corporation, plc operates as a neuroscience-based biotechnology
company primarily in Ireland and the United States. It operates through
two segments, Biopharmaceuticals and Elan Drug Technologies. The
Biopharmaceuticals segment engages in the research, development, and
commercialization of therapies in the areas of autoimmune diseases and
neurodegenerative diseases. The EDT segment engages in development, scale-up, and manufacture of
drug optimization technologies, including NanoCrystal technology that
involves reducing crystalline drug to particles under 400 nanometers.
Executives
G. Kelly Martin - CEO, President
Kryan McLaughlin - Chairman
